Metoprolol
- Generic Name
- Metoprolol
- Brand Names
- Kapspargo, Lopressor, Lopressor Hct, Toprol
- Drug Type
- Small Molecule
- Chemical Formula
- C15H25NO3
- CAS Number
- 51384-51-1
- Unique Ingredient Identifier
- GEB06NHM23
- Background
Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release. The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative. To this date, it is one of the preferre...
- Indication
Metoprolol is indicated for the treatment of angina, heart failure, myocardial infarction, atrial fibrillation, atrial flutter and hypertension.
Some off-label uses of metoprolol include supraventricular tachycardia and thyroid storm.
...
- Associated Conditions
- Angina Pectoris, Atrial Fibrillation, Hypertension, Migraine, Myocardial Infarction, Supraventricular Tachycardia (SVT), Thyroid Crisis, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III)
- Associated Therapies
- -
An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
- Conditions
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT06686628
- Locations
- 🇩🇪
Investigational Site Number : 2760001, Berlin, Germany
Aging, Beta Blockers, and Thermoregulatory Responses
- Conditions
- Interventions
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 22
- Registration Number
- NCT06582680
- Locations
- 🇺🇸
IEEM Texas Health Presbyterian Hospital Dallas, Dallas, Texas, United States
Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)
- Conditions
- Interventions
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Madeleine Puissant
- Target Recruit Count
- 20
- Registration Number
- NCT06569212
- Locations
- 🇺🇸
MaineHealth, Portland, Maine, United States
Detoxification From the Lipid Tract
- Conditions
- Interventions
- Device: electroencephalogram biofeedbackDevice: electrical brain stimulationDevice: ultra-low frequency transcranial magnetic stimulationDrug: Sertraline HydrochlorideDrug: ClonazepamDrug: AlprazolamDrug: MetoprololDrug: OlanzapineDrug: Pravastatin Sodium 20 MGDrug: Sacubitril Valsartan Sodium Hydrate
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Pachankis, Yang I., M.D.
- Target Recruit Count
- 1
- Registration Number
- NCT06357104
- Locations
- 🇨🇳
Residential Address, Chongqing, Chongqing, China
Determination of Drug Levels for Pharmacotherapy of Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- University Hospital Ostrava
- Target Recruit Count
- 100
- Registration Number
- NCT06035978
- Locations
- 🇨🇿
University Hospital Ostrava, Ostrava, Czech Republic, Czechia
Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 21
- Registration Number
- NCT05891119
- Locations
- 🇺🇸
Direct Helpers Research Center (DHRC), Hialeah, Florida, United States
🇺🇸Velocity Clinical Research -Spartanburg, Spartanburg, South Carolina, United States
🇺🇸DermDox Dermatology Centers, PC - Sugarloaf, Nashville, Tennessee, United States
A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT05741385
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
Effect and Safety of Flecainide and Metoprolol Versus Metoprolol Alone to Suppress Ventricular Arrhythmias in Arrhythmic Mitral Valve Prolapse
- Conditions
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05631730
- Locations
- 🇳🇴
Oslo University Hospital Rikshospitalet, Oslo, Norway
Heart Rate Controller in Computed Tomography Coronary Angiography
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 246
- Registration Number
- NCT05261464
- Locations
- 🇹🇭
Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital Mahidol University, Bangkok, Bangkoknoi, Thailand
PericOronary INflammaTion in Non-Obstructive Coronary Artery Disease
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 100
- Registration Number
- NCT05031520
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.